Compounded GLP-1: Shortage Rules and Legal Limits

Shortage status matters to both 503A pharmacies and 503B outsourcing facilities. It does not, by itself, establish that a particular prescription or seller complies with every applicable requirement. This explainer was checked against FDA guidance on October 6, 2026.

For a delayed Ozempic refill, our pen identification and availability guide explains which product to ask about and how a national shortage statement differs from a local dispensing answer.

How shortages affect 503A pharmacies

FDA explains that a drug on its shortage list is not considered commercially available for the 503A copy restriction. Other requirements, including an individual patient's valid prescription, still apply. Outside a shortage, restrictions apply to regular or inordinate production of essentially copies; the law does not prohibit every limited instance.¹

That distinction corrects an earlier version of this guide, which incorrectly said shortage status never affected the 503A pathway.

How shortages affect 503B outsourcing facilities

Shortage listing can affect both the copy restriction and eligibility to compound from bulk drug substances. The latter also has a separate clinical-need list. These are separate conditions, not a blanket license for any formulation. FDA's shortage guidance describes limited enforcement flexibility for existing orders after a listing ends.¹

What the current GLP-1 guidance says

FDA's April 1, 2026 update states that semaglutide and tirzepatide are on neither the shortage list nor the 503B bulks list. It also explains the 503A patient-specific significant-difference documentation and warns that adding B12 can still produce an essentially copy. The earlier transition periods are historical; they do not establish permission for a new order today.²

Read the dated FDA policy update before accepting an old shortage screenshot. The relevant question is the basis for the prescription being offered now.

Questions to ask before paying

Ask the prescriber and dispensing pharmacy:

• Which named facility will compound and dispense this prescription, and which pathway does it use?
• What current rule or patient-specific determination supports this preparation?
• Who documents the clinical difference, where relevant, and what is the difference for me?
• If the provider changes pharmacy or formulation, who explains the change before another charge?

A different concentration or added ingredient is not something this site can declare legally sufficient. A pharmacy's answer should be specific enough for your prescriber to assess. Save the answer with your prescription and purchase terms.

Regulatory status is a separate purchasing question

A transparent price does not establish compliance, and a regulatory explanation does not establish product safety. Use our pharmacy verification guide to check identities and our compounded semaglutide checklist to organize safety questions. For the product distinction, see compounded versus brand-name GLP-1.

If a provider cannot explain continuity of care when fulfillment changes, include that uncertainty in the decision alongside the six-month cost. This guide explains published federal guidance; it does not determine the legality or suitability of an individual prescription.